Search research articles
Contact Us
Filters
Showing results (61-70 of 85) with videos related to
Page
of 9
Sort By:
Circulation
|
September 28, 2011
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET)
Giuseppe Mancia, Helmut Schumacher, Josep Redon, et al.
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology
|
October 16, 2003
Hypertrophy at ECG and its regression during treatment survey (HEART survey). Rationale, design and baseline characteristics of patients
Paolo Verdecchia, Peter Sleight, Fausto Avanzini, et al.
Journal of Hypertension
|
June 10, 2009
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study
Peter Sleight, Josep Redon, Paolo Verdecchia, et al.
European Journal of Preventive Cardiology
|
November 6, 2013
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial
Hiddo J Lambers Heerspink, Peggy Gao, Dick de Zeeuw, et al.
International Journal of Cardiology
|
December 27, 2006
Home telemonitoring of vital signs and cardiorespiratory signals in heart failure patients: system architecture and feasibility of the HHH model
Gian Domenico Pinna, Roberto Maestri, David Andrews, et al.
European Journal of Preventive Cardiology
|
July 3, 2013
Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients
Mario T Kratz, Helmut Schumacher, Karen Sliwa, et al.
Journal of the American College of Cardiology
|
December 24, 2011
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial)
Josep Redon, Giuseppe Mancia, Peter Sleight, et al.
JAMA
|
November 24, 2011
Urinary sodium and potassium excretion and risk of cardiovascular events
Martin J O'Donnell, Salim Yusuf, Andrew Mente, et al.
Circulation
|
March 17, 2010
Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials
Michael Böhm, Magnus Baumhäkel, Koon Teo, et al.
Clinical Trials (London, England)
|
February 20, 2008
Specific barriers to the conduct of randomized trials
Lelia Duley, Karen Antman, Joseph Arena, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 85) with videos related to
Sort By:
Page
of 9
Circulation
|
September 28, 2011
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET)
Giuseppe Mancia, Helmut Schumacher, Josep Redon, et al.
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology
|
October 16, 2003
Hypertrophy at ECG and its regression during treatment survey (HEART survey). Rationale, design and baseline characteristics of patients
Paolo Verdecchia, Peter Sleight, Fausto Avanzini, et al.
Journal of Hypertension
|
June 10, 2009
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study
Peter Sleight, Josep Redon, Paolo Verdecchia, et al.
European Journal of Preventive Cardiology
|
November 6, 2013
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial
Hiddo J Lambers Heerspink, Peggy Gao, Dick de Zeeuw, et al.
International Journal of Cardiology
|
December 27, 2006
Home telemonitoring of vital signs and cardiorespiratory signals in heart failure patients: system architecture and feasibility of the HHH model
Gian Domenico Pinna, Roberto Maestri, David Andrews, et al.
European Journal of Preventive Cardiology
|
July 3, 2013
Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients
Mario T Kratz, Helmut Schumacher, Karen Sliwa, et al.
Journal of the American College of Cardiology
|
December 24, 2011
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial)
Josep Redon, Giuseppe Mancia, Peter Sleight, et al.
JAMA
|
November 24, 2011
Urinary sodium and potassium excretion and risk of cardiovascular events
Martin J O'Donnell, Salim Yusuf, Andrew Mente, et al.
Circulation
|
March 17, 2010
Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials
Michael Böhm, Magnus Baumhäkel, Koon Teo, et al.
Clinical Trials (London, England)
|
February 20, 2008
Specific barriers to the conduct of randomized trials
Lelia Duley, Karen Antman, Joseph Arena, et al.
Page
of 9